Data from Targeting FSTL1 Prevents Tumor Bone Metastasis and Consequent Immune Dysfunction

Abstract

<div>Abstract<p>Bone metastasis greatly deteriorates the quality of life in patients with cancer. Although mechanisms have been widely investigated, the relationship between cancer bone metastasis and antitumor immunity in the host has been much less studied. Here, we report a novel mechanism of bone metastasis mediated by FSTL1, a follistatin-like glycoprotein secreted by Snail<sup>+</sup> tumor cells, which metastasize frequently to bone. We found that FSTL1 plays a dual role in bone metastasis—in one way by mediating tumor cell invasion and bone tropism but also in a second way by expanding a population of pluripotent mesenchymal stem-like CD45<sup>−</sup>ALCAM<sup>+</sup> cells derived from bone marrow. CD45<sup>−</sup>ALCAM<sup>+</sup> cells induced bone metastasis <i>de novo</i>, but they also generated CD8<sup>low</sup> T cells with weak CTL activity in the periphery, which also promoted bone metastasis in an indirect manner. RNA interference-mediated attenuation of FSTL1 in tumor cells prevented bone metastasis along with the parallel increase in ALCAM<sup>+</sup> cells and CD8<sup>low</sup> T cells. These effects were accompanied by heightened antitumor immune responses <i>in vitro</i> and <i>in vivo</i>. In clinical specimens of advanced breast cancer, ALCAM<sup>+</sup> cells increased with FSTL1 positivity in tumor tissues, but not in adjacent normal tissues, consistent with a causal connection between these molecules. Our findings define FSTL1 as an attractive candidate therapeutic target to prevent or treat bone metastasis, which remains a major challenge in patients with cancer. <i>Cancer Res; 73(20); 6185–93. ©2013 AACR</i>.</p></div>